The bottleneck in drug discovery is often a simple, physical one. A chemist sketches a promising molecule on a whiteboard, but getting a physical sample to test can take a contract research organization (CRO) six weeks or more. Onepot.ai, a San Francisco startup that emerged from stealth last November, is betting that an AI chemist and a robotic lab can shrink that wait to about five days [C&EN, November 2025].
The AI Chemist and the Pot
The company’s system is built on two components. The first is Phil, an AI model trained on in-house experimental data and literature to plan chemical reactions. The second is POT-1, the robotic lab that executes them. A researcher submits a target molecule from Onepot’s enumerated catalog of 3.4 billion compounds; Phil devises a synthesis path, and POT-1’s robotic arms get to work [Onepot.ai research, 2026]. The platform currently supports staple reactions like Suzuki-Miyaura coupling and amide bond formation, with more in beta testing [Onepot.ai onePot_core.pdf, 2026].
The founding story is a classic one of frustration meeting capability. Co-founders Daniil Boiko and Andrei Tyrin met in a chemistry lab at M.V. Lomonosov Moscow State University and later built their first automated lab in March 2024 [C&EN, November 2025]. Boiko’s PhD work at Carnegie Mellon was central to Coscientist, an AI system that autonomously designs and executes complex experiments [CMU Engineering, December 2023].
Why Top-Tier Investors Wrote the Check
In November 2025, Onepot.ai announced a $13 million seed round led by Fifty Years. The investor list includes Khosla Ventures, Speedinvest, NAVEC, Norrsken VC, and angels including Google’s Jeff Dean and OpenAI co-founder Wojciech Zaremba [C&EN, November 2025].
This capital is earmarked for expanding the team and a second lab facility, aiming to turn the prototype into a reliable, scaled service [Yahoo Finance, November 2025].
The Incumbent Mountain to Climb
The ambition is clear, but the path runs directly through established giants. The primary competitive pressure comes from massive, global CROs like WuXi AppTec and Enamine. Their advantages are not trivial. They offer immense scale, decades of process expertise, and deeply entrenched relationships with every major pharma company. Onepot’s wedge is speed and, potentially, cost for early-stage discovery work.
- Process breadth. While Onepot supports several common reactions, drug discovery often requires exotic chemistries.
- Commercial proof. The company has not yet named any commercial customers or disclosed traction metrics.
- Operational scaling. Running one robotic lab for prototypes is one thing. Operating a fleet of them to meet commercial demand, with consistent yield and purity, is a formidable engineering and logistics challenge.
The bet, then, is that a 5-day turnaround is not just a nice-to-have but a fundamental accelerator for the iterative design-make-test-analyze (DMTA) cycles of modern drug discovery.